1334602-75-3

Upstream product

• 20776-50-5 2-amino-4-bromobenzoic acid 
• 194851-16-6 7-bromoquinazolin-4(3H)-one 
• 573675-55-5 7-bromo-4-chloro-quinazoline 
• 105-13-5 4-Methoxybenzyl alcohol 
• 194851-16-6 7-bromo-4-hydroxyquinazoline 
• 824-94-2 p-methoxybenzyl chloride 

Downstream Products

• 1334602-74-2 4-(4-chloroquinazolin-7-yl)morpholine 
• 1334602-76-4 4-(4-methoxybenzyloxy)-7-morpholin-4-yl-quinazoline 
• 1334600-89-3 7-morpholin-4-yl-4-((S)-3-phenyl-piperidin-1-yl)-quinazoline 

Relevant academic research and scientific papers

Quinazoline DNA-PK (deoxyribonucleic acid-polyketide) inhibitor

The invention belongs to the technical field of medicines, and particularly relates to quinazoline DNAPK inhibitor compounds, pharmaceutically acceptable salts or isomers thereof, pharmaceutical compositions and preparations containing the compounds, the pharmaceutically acceptable salts or the isomers thereof, and a method for preparing the compounds, the pharmaceutically acceptable salts or theisomers thereof, as well as uses of the compounds, pharmaceutically acceptable salts thereof, or isomers thereof.

FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST

The present invention relates to fused cyclic urea derivatives which have antagonistic activities against CRHR1 and/or CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR1 and/or CRHR2 is involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CRHR1 and/or CRHR2 is involved.

Morpholinylquinazolines

The invention relates to compounds of the formulae (I), (II) and (III) in which R1, R2, R3, R4, Y, W1, W2, L, A, Alk, Cyc, Ar, Het1, Het2, Hal and n have the meaning indicated in claim 1, and/or physiologically acceptable salts, tautomers and stereo-isomers thereof, including mixtures thereof in all ratios. The compounds of the formula (I) can be used for the inhibition of serine/threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation. The invention also relates to the use of the compounds of the formula (I) in the prophylaxis, therapy or progress control of cancer, tumours, metastases or angiogenesis disorders, in combination with radiotherapy and/or an anticancer agent. The invention furthermore relates to a process for the preparation of the compounds of the formula (I) by reaction of compounds of the formulae (II) and (III) and optionally conversion of a base or acid of the compounds of the formula (I) into one of their salts.